Literature DB >> 26818601

Double robust estimator of average causal treatment effect for censored medical cost data.

Xuan Wang1, Lauren A Beste2, Marissa M Maier3, Xiao-Hua Zhou1,4.   

Abstract

In observational studies, estimation of average causal treatment effect on a patient's response should adjust for confounders that are associated with both treatment exposure and response. In addition, the response, such as medical cost, may have incomplete follow-up. In this article, a double robust estimator is proposed for average causal treatment effect for right censored medical cost data. The estimator is double robust in the sense that it remains consistent when either the model for the treatment assignment or the regression model for the response is correctly specified. Double robust estimators increase the likelihood the results will represent a valid inference. Asymptotic normality is obtained for the proposed estimator, and an estimator for the asymptotic variance is also derived. Simulation studies show good finite sample performance of the proposed estimator and a real data analysis using the proposed method is provided as illustration.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  average causal treatment effect; censored data; double robust estimator; inverse probability weighted; lifetime medical cost data

Mesh:

Year:  2016        PMID: 26818601     DOI: 10.1002/sim.6876

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  Net-benefit regression with censored cost-effectiveness data from randomized or observational studies.

Authors:  Shuai Chen; Jeffrey S Hoch
Journal:  Stat Med       Date:  2022-06-03       Impact factor: 2.497

2.  Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.

Authors:  Marissa M Maier; Xiao-Hua Zhou; Michael Chapko; Steven L Leipertz; Xuan Wang; Lauren A Beste
Journal:  Dig Dis Sci       Date:  2018-02-16       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.